JAK Inhibitors: Treatment Efficacy and Safety Profile in Patients with Psoriasis

Janus kinase (JAK) pathways are key mediators in the immunopathogenesis of psoriasis. Psoriasis treatment has evolved with the advent of targeted therapies, which inhibit specific components of the psoriasis proinflammatory cascade. JAK inhibitors have been studied in early phase trials for psoriasi...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, Leeyen, Armstrong, April W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4027021/
https://www.ncbi.nlm.nih.gov/pubmed/24883332
http://dx.doi.org/10.1155/2014/283617

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4027021/
https://www.ncbi.nlm.nih.gov/pubmed/24883332
http://dx.doi.org/10.1155/2014/283617

Ejemplares similares